{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:58:01Z","timestamp":1789750681462,"version":"4.0.1"},"reference-count":72,"publisher":"Georg Thieme Verlag KG","issue":"10","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Venous thromboembolism (VTE) can present different challenging situations for which high-quality evidence to guide optimal preventive and therapeutic management is lacking and for which clinical practice guidelines have not established solid recommendations. The aim of this article is to achieve consensus on a proposal of action for the clinical management of complex, clinically relevant situations with a low level of evidence which generate great uncertainty\u2014the duration of VTE treatment and the role of thrombus recanalization, the prevention of VTE within the context of pregnancy, management of anticoagulant treatment in patients with VTE and special characteristics, such as renal insufficiency and obesity, the therapeutic management of pluripathological and polymedicated older patients with VTE, and finally, primary ambulatory thromboembolic prevention in cancer patients. This consensus article arose from a collaboration of experts in VTE from different medical specialties.<\/jats:p>","DOI":"10.1055\/a-2595-1811","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:09:48Z","timestamp":1747163388000},"page":"944-959","source":"Crossref","is-referenced-by-count":1,"title":["Consensus on the Management of the Clinical Challenges of Venous Thromboembolism in Special Situations"],"prefix":"10.1055","volume":"125","author":[{"given":"Cristina","family":"Marzo","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy Department, Hospital Universitari Arnau de Vilanova, Lleida, Catalunya, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Solanich","sequence":"additional","affiliation":[{"name":"Vascular Surgery Department, Hospital Universitari Parc Taul\u00ed, Sabadell, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Tassies","sequence":"additional","affiliation":[{"name":"Hemotherapy and Hemostasis Department, Hospital Clinic Barcelona, Barcelona, Catalunya, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pina","sequence":"additional","affiliation":[{"name":"Thrombosis and Haemostasis Department, Hospital Universitari Bellvitge, Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite Antonio","family":"Rebollo","sequence":"additional","affiliation":[{"name":"Oncogeriatrics Unit, Institut Catal\u00e0 d'Oncologia, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Oncology, Parc Taul\u00ed Hospital Universitari, Sabadell, Barcelona, Spain"},{"name":"Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT, Universitat Aut\u00f2noma de Barcelona, Sabadell, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Serradell","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Merino","sequence":"additional","affiliation":[{"name":"Medical Affairs Thrombosis, LEO Pharma Spain, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Carrasco","sequence":"additional","affiliation":[{"name":"Unitat d'Hemostasia i Trombosi, Servei d'Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Tugues","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy Department, Hospital Universitario Arnau de Vilanova de Lleida, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1055\/s-0038-1676611","article-title":"Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry","volume":"119","author":"W Ageno","year":"2019","journal-title":"Thromb Haemost"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.thromres.2022.08.015","article-title":"Challenging clinical scenarios for therapeutic anticoagulation: a practical approach","volume":"218","author":"K L Martens","year":"2022","journal-title":"Thromb Res"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"C A Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","article-title":"Editor's choice\u2014European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis","volume":"61","author":"S K Kakkos","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1055\/s-0040-1721735","article-title":"Anticoagulation for patients with venous thromboembolism: when is extended treatment required?","volume":"4","author":"J I Weitz","year":"2020","journal-title":"TH Open"},{"issue":"08","key":"ref6","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/eurjpc\/zwab088","article-title":"Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function","volume":"29","author":"L Mazzolai","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejvs.2004.02.029","article-title":"Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial","volume":"29","author":"M E Daskalopoulos","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"},{"issue":"08","key":"ref9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.amjmed.2011.02.033","article-title":"Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review","volume":"124","author":"R D Hull","year":"2011","journal-title":"Am J Med"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.amjmed.2008.12.023","article-title":"Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome","volume":"122","author":"R D Hull","year":"2009","journal-title":"Am J Med"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1538-7836.2011.04254.x","article-title":"Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis","volume":"9","author":"M Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejvs.2009.11.022","article-title":"Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study","volume":"39","author":"B Cosmi","year":"2010","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1160\/TH13-04-0336","article-title":"Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis","volume":"111","author":"M P Donadini","year":"2014","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1055\/a-2059-4737","article-title":"Residual venous obstruction as an indicator of clinical outcomes following deep vein thrombosis: a management study","volume":"123","author":"A FJ Iding","year":"2023","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1538-7836.2011.04240.x","article-title":"Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study","volume":"9","author":"G LE Gal","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"21","key":"ref16","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1182\/blood.V124.21.4277.4277","article-title":"Cancer-associated deep vein thrombosis: the role of residual vein thrombosis for assessing the duration of low molecular weight heparin (the EXTENDED Cancer-DACUS)","volume":"124","author":"M Napolitano","year":"2014","journal-title":"Blood"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"2241527","DOI":"10.1080\/01443615.2023.2241527","article-title":"Swedish obstetric thromboprophylaxis guideline: background and update","volume":"43","author":"P G Lindqvist","year":"2023","journal-title":"J Obstet Gynaecol"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2002-01-0149","article-title":"Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism","volume":"100","author":"I Pabinger","year":"2002","journal-title":"Blood"},{"issue":"22","key":"ref19","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1182\/bloodadvances.2018024802","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy","volume":"2","author":"S M Bates","year":"2018","journal-title":"Blood Adv"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed","volume":"141","author":"S M Bates","year":"2012","journal-title":"Chest"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1055\/a-1132-0750","article-title":"Prevention of venous thromboembolism during pregnancy and the puerperium with a special focus on women with hereditary thrombophilia or prior VTE. Position paper of the working group in women's health of the Society of Thrombosis and Haemostasis (GTH)","volume":"40","author":"C Hart","year":"2020","journal-title":"Hamostaseologie"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","article-title":"ACOG Practice Bulletin No. 196: thromboembolism in pregnancy","volume":"132","author":"American College of Obstetricians and Gynecologists' Committee on Practice Bulletins\u2014Obstetrics","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1701-2163(15)30569-7","article-title":"Venous thromboembolism and antithrombotic therapy in pregnancy","volume":"36","author":"W S Chan","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(22)02128-6","article-title":"Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial","volume":"400","author":"I M Bistervels","year":"2022","journal-title":"Lancet"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/asheducation-2016.1.188","article-title":"Thrombosis and anticoagulation in the setting of renal or liver disease","volume":"2016","author":"C Ribic","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MCP.0b013e32832ee371","article-title":"Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms","volume":"15","author":"K Wattanakit","year":"2009","journal-title":"Curr Opin Pulm Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2022.08.001","article-title":"Long-term clinical outcomes in older patients with acute venous thromboembolism who have renal impairment","volume":"218","author":"M Messi","year":"2022","journal-title":"Thromb Res"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/rth2.12250","article-title":"Atrial fibrillation in patients with end-stage renal disease on hemodialysis: magnitude of the problem and new approach to oral anticoagulation","volume":"3","author":"O K\u00f6nigsbr\u00fcgge","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"22","key":"ref30","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"D M Witt","year":"2018","journal-title":"Blood Adv"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"10","key":"ref36","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00228-022-03365-4","article-title":"Tinzaparin\u2014a review of its molecular profile, pharmacology, special properties, and clinical uses","volume":"78","author":"M Amerali","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40256-019-00382-0","article-title":"Tinzaparin sodium pharmacokinetics in patients with chronic kidney disease: practical implications","volume":"20","author":"H Helfer","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pace.13331","article-title":"Safety and efficacy of apixaban versus warfarin in patients with end stage renal disease: meta-analysis","volume":"41","author":"R Chokesuwattanaskul","year":"2018","journal-title":"Pacing Clin Electrophysiol"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4212\/cjhp.v68i1.1423","article-title":"Measuring anti-factor Xa activity to monitor low-molecular-weight heparin in obesity: a critical review","volume":"68","author":"G Egan","year":"2015","journal-title":"Can J Hosp Pharm"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","article-title":"SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)","volume":"22","author":"A J Mu\u00f1oz Mart\u00edn","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2022.04.011","article-title":"Body weight adapted tinzaparin treatment in patients with obesity","volume":"214","author":"C Pfrepper","year":"2022","journal-title":"Thromb Res"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1055\/s-0038-1677019","article-title":"Weight-based enoxaparin for venous thromboembolism in obesity gives similar anti-Xa levels to patients <100\u2009kg, with no increase in major bleeding","volume":"45","author":"K H Maclachlan","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"19","key":"ref49","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"T L Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"A Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"D Garcia","year":"2012","journal-title":"Chest"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"issue":"08","key":"ref53","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"K A Martin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"20","key":"ref54","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/archinte.164.20.2260","article-title":"Venous thromboembolism according to age: the impact of an aging population","volume":"164","author":"P D Stein","year":"2004","journal-title":"Arch Intern Med"},{"issue":"05","key":"ref55","first-page":"302","article-title":"Anticoagulants in frail patients. Seven situations at risk","volume":"43","author":"I Elalamy","year":"2018","journal-title":"J Med Vasc"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"e014108","DOI":"10.1161\/JAHA.119.014108","article-title":"Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study","volume":"9","author":"S Sanghai","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/ageing\/afz021","article-title":"Understanding and improving multidisciplinary team working in geriatric medicine","volume":"48","author":"G Ellis","year":"2019","journal-title":"Age Ageing"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0749-0690(05)70108-7","article-title":"Treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin in the geriatric patient population","volume":"17","author":"G J Merli","year":"2001","journal-title":"Clin Geriatr Med"},{"issue":"06","key":"ref59","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1055\/s-0037-1615034","article-title":"Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)","volume":"79","author":"P Mismetti","year":"1998","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref60","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00002018-200225100-00005","article-title":"Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients","volume":"25","author":"E Pautas","year":"2002","journal-title":"Drug Saf"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-12-21","article-title":"Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants","volume":"12","author":"V Geldhof","year":"2014","journal-title":"Thromb J"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"M H Prins","year":"2013","journal-title":"Thromb J"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2017.12.005","article-title":"Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: an analysis of the randomized, double-blind Hokusai-VTE trial","volume":"162","author":"T Vanassche","year":"2018","journal-title":"Thromb Res"},{"issue":"08","key":"ref64","first-page":"1046","article-title":"Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE)","volume":"91","author":"L L\u00f3pez-Jim\u00e9nez","year":"2006","journal-title":"Haematologica"},{"issue":"04","key":"ref65","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1055\/s-0038-1676359","article-title":"Outcomes beyond the third month of anticoagulation in patients aged >75 years with a first episode of unprovoked venous thromboembolism","volume":"2","author":"A I\u00f1urrieta","year":"2018","journal-title":"TH Open"},{"issue":"02","key":"ref66","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/cancers16020458","article-title":"Novel insights in venous thromboembolism risk assessment methods in ambulatory cancer patients: from the guidelines to clinical practice","volume":"16","author":"A Dr\u0103gan","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"14","key":"ref67","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"F I Mulder","year":"2021","journal-title":"Blood"},{"issue":"21","key":"ref68","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V118.21.674.674","article-title":"Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among US cancer patients","volume":"118","author":"A A Khorana","year":"2011","journal-title":"Blood"},{"issue":"10","key":"ref69","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s12094-014-1165-y","article-title":"Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model","volume":"16","author":"A J Mu\u00f1oz Mart\u00edn","year":"2014","journal-title":"Clin Transl Oncol"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cllc.2019.06.012","article-title":"ROS1-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS)","volume":"21","author":"R Chiari","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cllc.2016.10.007","article-title":"ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism","volume":"18","author":"A Zer","year":"2017","journal-title":"Clin Lung Cancer"},{"issue":"05","key":"ref72","doi-asserted-by":"crossref","first-page":"1702431","DOI":"10.1183\/13993003.02431-2017","article-title":"Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer","volume":"51","author":"J Zugazagoitia","year":"2018","journal-title":"Eur Respir J"},{"issue":"16","key":"ref73","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.22.01542","article-title":"Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems","volume":"41","author":"A Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref74","first-page":"103405","article-title":"Primary prevention of cancer-associated venous thrombosis: rationale and challenges in clinical practice","volume":"71","author":"I Elalamy","year":"2023","journal-title":"Curr Res Transl Med"},{"issue":"07","key":"ref75","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"I Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"issue":"16","key":"ref76","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.22.00255","article-title":"A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective cohorts","volume":"41","author":"A Mu\u00f1oz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"ref77","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"N S Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref78","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"07","key":"ref79","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"D Farge","year":"2022","journal-title":"Lancet Oncol"},{"issue":"20","key":"ref81","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2020003115","article-title":"Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis","volume":"4","author":"F TM Bosch","year":"2020","journal-title":"Blood Adv"},{"issue":"03","key":"ref82","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MBC.0000000000000413","article-title":"Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"N M Tun","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"03","key":"ref83","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3324\/haematol.2019.221424","article-title":"Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients","volume":"105","author":"C Becattini","year":"2020","journal-title":"Haematologica"},{"issue":"08","key":"ref84","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/cancers12082028","article-title":"Primary thromboprophylaxis in ambulatory pancreatic cancer patients receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"C Frere","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2595-1811.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T23:09:42Z","timestamp":1758668982000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2595-1811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,9,23]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2595-1811","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}